Gilead Sciences
LKFT icon

Gilead Sciences’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Gilead Sciences’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$501M Hold
16,707,477
– – 34.24% 2
2026
Q2 		$500M Hold
16,707,477
– – 30.34% 2
2026
Q1 		$501M Hold
16,707,477
– – 23.67% 3
2025
Q4 		$551M Hold
16,707,477
– – 28.45% 2
2025
Q3 		$579M Hold
16,707,477
– – 32.31% 1
2025
Q2 		$468M Hold
16,707,477
– – 36.53% 1
2025
Q1 		$419M Hold
16,707,477
– – 35.5% 2
2024
Q4 		$462M Buy
+16,707,477
New +$466M 29.77% 2

Other funds holding LKFT

ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Crossmark Global Holdings
Crossmark Global Holdings Houston, Texas $7.69B AUM 31.68% 1-Year Est. Return
MQS Management
MQS Management New York $171M AUM 3.86% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Evergreen Capital Management
Evergreen Capital Management Bellevue, Washington $5.65B AUM 21.62% 1-Year Est. Return
SignatureFD
SignatureFD Atlanta, Georgia $7.76B AUM 16.09% 1-Year Est. Return
China Universal Asset Management Company
China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Cacti Asset Management
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return

Gilead Sciences's LKFT Position: Q3 2026 in Review

Gilead Sciences held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q3 2026 at 16,707,477 shares worth $501M. The position accounts for 34.24% of the portfolio, ranked #2.

Gilead Sciences first reported a position in LKFT in Q4 2024 and has held it in 8 quarters since. The position peaked at $579M in Q3 2025. 28 funds tracked by Wall St. Rank hold LKFT as of Q3 2026.

  • Gilead Sciences held 16,707,477 shares of Lakefront Biotherapeutics American Depositary Shares worth $501M as of Q3 2026.
  • Gilead Sciences left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q3 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up 34.24% of Gilead Sciences's portfolio in Q3 2026, its #2 holding.
  • Gilead Sciences first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2024 and has held it in 8 quarters since.
  • Gilead Sciences's Lakefront Biotherapeutics American Depositary Shares position peaked at $579M in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q3 2026.

Based on Gilead Sciences's 13F filing for Q3 2026, filed 6 Nov 2026.